Migräne (Topiramate)

Topiramate works by enhancing the inhibitory neurotransmitter GABA at GABA‑A receptors, blocking excitatory AMPA/kainate glutamate receptors, and inhibiting carbonic anhydrase enzymes. These actions collectively decrease neuronal excitability, stabilize neuronal membranes, and limit the spread of abnormal electrical activity in the brain.

The dose of topiramate is individualized and set by the prescribing healthcare professional. Typically, treatment begins with a low dose that is gradually increased based on therapeutic response and tolerability, with the prescriber determining the final maintenance dose.

The safety of topiramate in pregnancy and lactation has not been definitively established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made in consultation with a qualified healthcare provider.

To order Migräne, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Topiramate differs from other migraine preventives such as beta‑blockers or CGRP antagonists by targeting neuronal excitability through GABA enhancement and glutamate inhibition. While beta‑blockers act on vascular pathways and CGRP agents block peptide receptors, topiramate offers a distinct mechanism that may be preferred when those classes are contraindicated or ineffective.

Migräne tablets should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture, and avoid exposure to direct sunlight. Do not refrigerate or freeze the tablets.

Migräne is taken orally as a tablet, usually with a glass of water. The prescriber will advise whether it should be taken with food or on an empty stomach, and the dosing schedule should be followed exactly as instructed.

Serious risks include vision problems such as acute myopia or secondary angle‑closure glaucoma, and mood changes including depression or suicidal thoughts. Metabolic acidosis and the formation of kidney stones are also rare but potentially severe adverse events that require monitoring.

Migräne should not be used by individuals with a known hypersensitivity to topiramate or any of its excipients. Patients with severe renal impairment, a history of metabolic acidosis, or those who are pregnant should avoid the medication unless a healthcare professional determines that the benefits outweigh the risks.